HEI Inc. posted its first profit in three years Monday, and investors seem increasingly confident that CEO Mark Thomas is delivering on his turnaround plan for the Victoria-based technology firm. Since late December, HEI's share price has surged almost 30 percent.
To 97 cents.
This makes HEI a penny stock, a phrase that conjures all sorts of unpleasant connotations. Further, HEI's shares are not listed on an exchange like Nasdaq, but quoted on the "pink sheets," where it can be difficult to separate the legitimate businesses from orchestrated pump-and-dump investment scams.
HEI is a real business. Last year, customers bought $37 million worth of the microelectronic devices and components that it designs and manufactures for the medical, industrial and computer markets. But since 2008 it's been confined it to the purgatory of the pink sheets, and it may be stuck there for a while because the ecosystem that used to finance, nurture and promote small Minnesota companies like HEI is mostly gone.
The impact of this change has been especially noticeable in the Twin Cities, once home to a robust investment community that underwrote, sold and promoted microcap -- less than $10 million -- stock offerings for young Minnesota companies.
These were homegrown companies financed largely by hometown investors, who were rounded up by firms such as John G. Kinnard, R.J. Steichen, Miller Johnson & Kuehn, Equity Securities and others.
At the risk of waxing too nostalgic, let's acknowledge upfront that these firms brought their share of dogs to market, including one company, Endotronics, that was an outright fraud.
But both Control Data Corp. and Medtronic came public through local investment firms, and right up until the mid-'90s it remained a popular way for new companies to raise money. Summit Securities took CNS, the company that introduced the Breathe Right nasal strip, public at $1.99 a share, raising $2.8 million. Fifteen years later Europe's largest drugmaker, GlaxoSmithKline, paid more than $36 a share to acquire CNS.